AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38383476 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium bread (280 mg Na/100 g) in Group C
Number of subjects: 57
Study 38383476 — intervention group
Group type: COMPARATOR
Intervention: Standard bread (750 mg Na/100 g) in Group A
Number of subjects: 57
Study 38383476 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet with standard bread in Group B
Number of subjects: 57
Study 38383530 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted partial knee arthroplasty
Number of subjects: 64
Study 38383530 — intervention group
Group type: COMPARATOR
Intervention: Manual total knee arthroplasty
Number of subjects: 64
Study 38383578 — intervention group
Group type: EXPERIMENTAL
Intervention: AKS-452 (90 µg subcutaneous booster dose)
Number of subjects: 71
Study 38383794 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-reduction to <2000 steps for 2 weeks followed by 4 weeks of exercise rehabilitation 4 times per week
Number of subjects: 66
Study 38383794 — intervention group
Group type: COMPARATOR
Intervention: Control group continued habitual physical activity with no additional exercise intervention
Number of subjects: 66
Study 38383961 — intervention group
Group type: EXPERIMENTAL
Intervention: Daprodustat
Number of subjects: 0
Study 38383961 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38384122 — intervention group
Group type: EXPERIMENTAL
Intervention: Four Square Step Test (FSST) under dual-task (DT) conditions
Number of subjects: 30
Study 38384122 — intervention group
Group type: COMPARATOR
Intervention: Timed Up and Go (TUG) under single-task condition
Number of subjects: 30
Study 38384122 — intervention group
Group type: COMPARATOR
Intervention: Hospital for Special Surgery (HSS) Knee Score
Number of subjects: 30
Study 38384123 — intervention group
Group type: COMPARATOR
Intervention: Radial shockwave therapy (RSWT) - five treatments (one week apart over five-week period) to the three most painful areas (500 shocks at 1.5 bar and 15 Hz, then 1000 shocks at 2 bar and 8 Hz, and finally 500 shocks at 1.5 bar and 15 Hz)
Number of subjects: 0
Study 38384123 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (placebo)
Number of subjects: 0
Study 38384142 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Distress Scale (four domains: regimen, emotional, interpersonal, healthcare provider)
Number of subjects: 0
Study 38384179 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflamed tissue obtained from the most active lesion
Number of subjects: 47
Study 38384179 — intervention group
Group type: COMPARATOR
Intervention: Uninflamed tissue collected from approximately 15 cm above the upper end of the active lesion
Number of subjects: 47
Study 38384245 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV-mediated gene therapy for genetic diseases
Number of subjects: 400000000
Study 38384245 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy products
Number of subjects: 400000000
Study 38384289 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexasodium fytate
Number of subjects: 0
Study 38384289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38384338 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 357
Study 38384338 — intervention group
Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 357
Study 38384338 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine and SSRIs
Number of subjects: 357
Study 38384348 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + CT
Number of subjects: 120
Study 38384348 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + M4H
Number of subjects: 120
Study 38384348 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + MCT
Number of subjects: 120
Study 38384348 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 120
Study 38384390 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based therapy (EXP)
Number of subjects: 102
Study 38384390 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation (BA)
Number of subjects: 102
Study 38384458 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial infusion of TMZ-resistant γδ T cells (genetically engineered with p140K/MGMT lentivector)
Number of subjects: 0
Study 38384458 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of Temozolomide (TMZ)
Number of subjects: 0
Study 38384458 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Resistance Immunotherapy (DRI) combining TMZ and TMZ-resistant γδ T cells
Number of subjects: 0
Study 38384801 — intervention group
Group type: EXPERIMENTAL
Intervention: UV1 vaccination in combination with pembrolizumab
Number of subjects: 0
Study 38384801 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab as a single agent
Number of subjects: 0
Study 38384879 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and strategies for self-managing symptoms of Long COVID (PASC)
Number of subjects: 0
Study 38384923 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovation Lab (week-long immersive collaboration experience)
Number of subjects: 95
Study 38384923 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 95
Study 38385031 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 positive individuals
Number of subjects: 404
Study 38385031 — intervention group
Group type: COMPARATOR
Intervention: SARS-CoV-2 negative individuals
Number of subjects: 404
Study 38385137 — intervention group
Group type: EXPERIMENTAL
Intervention: C-ESWT (200 shots/spot at 0.09 mJ/mm²)
Number of subjects: 64
Study 38385137 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study 38385243 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil plus subcutaneous rituximab induction and maintenance
Number of subjects: 112
Study 38385243 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab maintenance
Number of subjects: 112
Study 38385243 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil plus rituximab (induction phase)
Number of subjects: 112
Study 38385529 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentaspline pulsed-field ablation catheter
Number of subjects: 179
Study 38385566 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1345 (12.5, 25, 50, 100, or 200 µg)
Number of subjects: 298
Study 38385566 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1345 (first injection)
Number of subjects: 298
Study 38385566 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1345 (12-month booster)
Number of subjects: 298
Study 38385566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 38385587 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate (145 mg tablet daily or on alternate days for those with impaired renal function)
Number of subjects: 1151
Study 38385922 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendyne transcatheter mitral valve replacement (TMVR)
Number of subjects: 195
Study 38385926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy (IVL)
Number of subjects: 426
Study 38385926 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 426
Study 38385941 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 448
Study 38385941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study 38386005 — intervention group
Group type: EXPERIMENTAL
Intervention: Race-specific equations in pulmonary function tests
Number of subjects: 0
Study 38386005 — intervention group
Group type: COMPARATOR
Intervention: Standard pulmonary function tests
Number of subjects: 0
Study 38386030 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified HEMSTOP score including gingival bleeding
Number of subjects: 117
Study 38386030 — intervention group
Group type: COMPARATOR
Intervention: HEMSTOP score without gingival bleeding
Number of subjects: 117
Study 38386030 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival bleeding
Number of subjects: 117
Study 38386029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat Mass Index (FMI)
Number of subjects: 1422
Study 38386029 — intervention group
Group type: COMPARATOR
Intervention: Body Mass Index (BMI)
Number of subjects: 1422
Study 38386051 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurospeed semi-compliant balloon
Number of subjects: 8
Study 38386178 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg every 4 weeks (Q4W)
Number of subjects: 739
Study 38386178 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg every 8 weeks (Q8W)
Number of subjects: 739
Study 38386178 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 739
Study 38386178 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab (Q4W and Q8W)
Number of subjects: 739
Study 38386180 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone oil removal
Number of subjects: 30
Study 38386266 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative 1 mg dexamethasone suppression test
Number of subjects: 32
Study 38386266 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of diabetes
Number of subjects: 32
Study 38386266 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH levels
Number of subjects: 32
Study 38386322 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That HEAL (CTH) intervention
Number of subjects: 8166963
Study 38386322 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 8166963
Study 38386376 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth platform for cardiac rehabilitation
Number of subjects: 79
Study 38386376 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for regular physical exercise
Number of subjects: 79
Study 38386376 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of information on diagnosis, current medication, test results, and risk scores
Number of subjects: 79
Study 38386376 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized care support
Number of subjects: 79
Study 38386376 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance of eHealth components
Number of subjects: 79
Study 38386396 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media intervention promoting guideline-related goals for increased physical activity, healthy eating, HPV vaccination, and reduced nicotine product use, alcohol intake, and solar UV radiation exposure, delivered over 12 months in Facebook private groups.
Number of subjects: 1000
Study 38386396 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media intervention
Number of subjects: 1000
Study 38386434 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-Derived Open-Source Automated Insulin Delivery Loop System
Number of subjects: 0
Study 38386438 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Glargine 300 U/mL
Number of subjects: 0
Study 38386436 — intervention group
Group type: EXPERIMENTAL
Intervention: Clock-Based Nocturnal Hypoglycemia
Number of subjects: 0
Study 38386436 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia While Asleep
Number of subjects: 0
Study 38386505 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intra-articular injection of GMP manufactured stromal vascular fraction (SVF)
Number of subjects: 29
Study 38386795 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 38386949 — intervention group
Group type: EXPERIMENTAL
Intervention: Zagotenemab 1,400 mg
Number of subjects: 360
Study 38386949 — intervention group
Group type: EXPERIMENTAL
Intervention: Zagotenemab 5,600 mg
Number of subjects: 360
Study 38386949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 38386978 — intervention group
Group type: EXPERIMENTAL
Intervention: rilzabrutinib 400 mg twice daily
Number of subjects: 16
Study 38387470 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis E vaccine (three doses administered intramuscularly at month 0, month 1, and month 6)
Number of subjects: 112604
Study 38387470 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three doses administered intramuscularly at month 0, month 1, and month 6)
Number of subjects: 112604
Study 38387597 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) treatment applied once per week for 3 weeks
Number of subjects: 40
Study 38387597 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) treatment
Number of subjects: 40
Study 38387597 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment applied once per week for 3 weeks
Number of subjects: 40
Study 38387646 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids and itraconazole
Number of subjects: 132
Study 38387646 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 132
Study 38387980 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care model
Number of subjects: 40
Study 38387980 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 38387978 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency data collection and analysis techniques, novel clinical interventions, and comparative effectiveness methodology.
Number of subjects: 300
Study 38387978 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection from ICU treatment for specific aspects of msTBI care.
Number of subjects: 300
Study 38387978 — intervention group
Group type: EXPERIMENTAL
Intervention: Reports documenting performance on selected key quality indicators.
Number of subjects: 300
Study 38387984 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term use of CNSDs
Number of subjects: 246
Study 38387984 — intervention group
Group type: EXPERIMENTAL
Intervention: Surviving users of CNSDs
Number of subjects: 246
Study 38387984 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 246
Study 38387984 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 246
Study 38387985 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth-centred Participatory Action (YoPA) project interventions
Number of subjects: 800
Study 38387989 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC)
Number of subjects: 144
Study 38387989 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 144
Study 38387989 — intervention group
Group type: COMPARATOR
Intervention: S/CPS
Number of subjects: 144
Study 38388014 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (auricular neuromodulation)
Number of subjects: 30
Study 38388014 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 38388017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency (RF) treatment
Number of subjects: 49
Study 38388017 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiofrequency (RF) treatment
Number of subjects: 49
Study 38388017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled RF treatment in PPSP
Number of subjects: 49
Study 38388017 — intervention group
Group type: COMPARATOR
Intervention: Conventional RF treatment in PPSP
Number of subjects: 49
Study 38388017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled RF treatment in OA
Number of subjects: 49
Study 38388017 — intervention group
Group type: COMPARATOR
Intervention: Conventional RF treatment in OA
Number of subjects: 49
Study 38388019 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulation (n=15)
Number of subjects: 30
Study 38388019 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (n=15)
Number of subjects: 30
Study 38388022 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone game intervention for HIV prevention; details on dosage and duration not available.
Number of subjects: 0
Study 38388022 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; details on intervention or control not available.
Number of subjects: 0
Study 38388167 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus famitinib
Number of subjects: 41
Study 38388171 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (160 mg every 4 weeks)
Number of subjects: 400
Study 38388171 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Bimekizumab (receiving bimekizumab from week 16 to 52)
Number of subjects: 400
Study 38388189 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day
Number of subjects: 39
Study 38388189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 38388236 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster shot with Sabin inactivated poliomyelitis vaccine
Number of subjects: 1200
Study 38388444 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy with sealant Glubran 2®
Number of subjects: 0
Study 38388444 — intervention group
Group type: COMPARATOR
Intervention: Lymphadenectomy without sealant (control group)
Number of subjects: 0
Study 38388470 — intervention group
Group type: EXPERIMENTAL
Intervention: PIMSRA
Number of subjects: 27
Study 38388489 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (outdoor intervention + indoor air purification with HEPA filters)
Number of subjects: 182
Study 38388489 — intervention group
Group type: COMPARATOR
Intervention: No intervention (controls)
Number of subjects: 182
Study 38388571 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with a lower-extremity powered exoskeleton (Exo) for 8 weeks, 2 times per week.
Number of subjects: 27
Study 38388571 — intervention group
Group type: COMPARATOR
Intervention: Exercise without a lower-extremity powered exoskeleton (Nxo) for 8 weeks, 2 times per week.
Number of subjects: 27
Study 38388646 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous cytarabine (100 mg/m2 for 5 days) administered in 35-day cycles for 12 total cycles
Number of subjects: 61
Study 38388715 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased social distancing (SDI)
Number of subjects: 0
Study 38388986 — intervention group
Group type: EXPERIMENTAL
Intervention: RBP-7000 (180 mg monthly injections)
Number of subjects: 23
Study 38388987 — intervention group
Group type: EXPERIMENTAL
Intervention: P11-4 varnish
Number of subjects: 66
Study 38388987 — intervention group
Group type: EXPERIMENTAL
Intervention: NSF varnish
Number of subjects: 66
Study 38388987 — intervention group
Group type: COMPARATOR
Intervention: NaF varnish
Number of subjects: 66
Study 38389038 — intervention group
Group type: EXPERIMENTAL
Intervention: Travel distance > 60 km
Number of subjects: 1436
Study 38389038 — intervention group
Group type: EXPERIMENTAL
Intervention: Travel distance median 40.96 km (IQR: 17.12, 63.49)
Number of subjects: 1436
Study 38389050 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Natural Apophyseal Glides (SNAGs)
Number of subjects: 38
Study 38389050 — intervention group
Group type: COMPARATOR
Intervention: Rocabado 6 × 6 program
Number of subjects: 38
Study 38389078 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg once daily for 28 days (group A)
Number of subjects: 220
Study 38389078 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 220
Study 38389113 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D HD system
Number of subjects: 48
Study 38389113 — intervention group
Group type: COMPARATOR
Intervention: 2D 4K system
Number of subjects: 48
Study 38389458 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual Health Intervention for Men
Number of subjects: 90
Study 38389458 — intervention group
Group type: COMPARATOR
Intervention: Referral and information control
Number of subjects: 90
Study 38389469 — intervention group
Group type: EXPERIMENTAL
Intervention: DragonFly system for transcatheter valve repair
Number of subjects: 120
Study 38389481 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipping Point Program (TPP)
Number of subjects: 1275
Study 38389481 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipping Point Program Plus (TPP+)
Number of subjects: 1275
Study 38389481 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1275
Study 38389759 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 0
Study 38389759 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 0
Study 38389985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 85
Study 38389985 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing-based yoga practice (Sudarshan Kriya Yoga; SKY)
Number of subjects: 85
Study 38390383 — intervention group
Group type: EXPERIMENTAL
Intervention: KC@H programme (internet-based sessions of therapeutic exercises at home and conventional CR sessions)
Number of subjects: 0
Study 38390383 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinic-based rehabilitation (CR)
Number of subjects: 0
Study 38390395 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperbaric spinal bupivacaine 0.5%, 1.3 ml (0.65 mg)
Number of subjects: 280
Study 38390658 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary RPL (two or more pregnancy losses before the first live birth)
Number of subjects: 184241
Study 38390658 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary RPL (RPL patients with no or one pregnancy loss before the first live birth)
Number of subjects: 184241
Study 38390658 — intervention group
Group type: COMPARATOR
Intervention: Individuals without RPL
Number of subjects: 184241
Study 38390658 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy complications at first and second live births in patients with primary RPL
Number of subjects: 184241
Study 38390658 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative second live birth rates in patients with primary RPL
Number of subjects: 184241
Study 38390793 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin added to standard of care
Number of subjects: 0
Study 38390795 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma 4β-hydroxycholesterol (4βHC) concentration
Number of subjects: 1946
Study 38390795 — intervention group
Group type: COMPARATOR
Intervention: Low plasma 4β-hydroxycholesterol (4βHC) concentration
Number of subjects: 1946
Study 38390800 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2, GDF-15, NT-proBNP (cardiac biomarkers)
Number of subjects: 566